Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
about
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatmentThe interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral TherapyDevelopment of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infectionAntiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.Frequent malaria illness episodes in two Malawian patients on antiretroviral therapy soon after stopping cotrimoxazole preventive therapy.CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in -negative HIV-infected Malawian adults stabilized on antiretroviral therapyEffect of pregnancy on the pharmacokinetic interaction between efavirenz and lumefantrine in HIV-malaria co-infectionThe Burden of Adverse Drug Reactions Due to Artemisinin-Based Antimalarial Treatment in Selected Ugandan Health Facilities: An Active Follow-Up Study
P2860
Q35583982-E51089F6-40FB-4EF2-89BE-11CC644F07B5Q35906361-0B6BA07A-C806-4D1B-9D1A-52B04C019186Q36290691-E29C004C-5E30-4F10-9318-E2557C224E1FQ36320042-16EC4BCE-5B59-49BC-B2DC-20BCC13F6AEAQ37096787-85A2DBE9-EB0C-43CD-B0B8-AFD17C45A0D7Q37279764-952C604C-77FB-4378-A3AB-84C69508E212Q37613241-506EBB90-4038-41F4-9180-FEAE8CAC994AQ40190013-FEB44EB6-06EA-4159-8492-B87270535A78Q41240864-9796D94E-12F7-4CC6-9C77-C3169721989CQ46398741-5133C2E8-A616-4E37-A532-6517864AAADAQ46405195-7BBD55F4-46E5-4826-A88C-75D8FA519472Q56339581-8E69B682-7EFD-4645-B8F0-95ED33480CF5Q56346858-6A2C05FF-6940-4E01-BA33-EA10C5165616Q56350030-E46984E8-DF3A-4218-B5B8-7D7A961BCF35
P2860
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Artemether-lumefantrine co-adm ...... netics and dosing implications
@ast
Artemether-lumefantrine co-adm ...... netics and dosing implications
@en
type
label
Artemether-lumefantrine co-adm ...... netics and dosing implications
@ast
Artemether-lumefantrine co-adm ...... netics and dosing implications
@en
prefLabel
Artemether-lumefantrine co-adm ...... netics and dosing implications
@ast
Artemether-lumefantrine co-adm ...... netics and dosing implications
@en
P2093
P2860
P50
P356
P1476
Artemether-lumefantrine co-adm ...... netics and dosing implications
@en
P2093
Angela Äbelö
Concepta Merry
Michael Ashton
Mohammed Lamorde
Pauline Byakika-Kibwika
Richard M Hoglund
Warunee Hanpithakpong
P2860
P304
P356
10.1111/BCP.12529
P407
P577
2015-04-01T00:00:00Z